Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399402 | 0.91 | ALDH1A1 (0.65) | MAPTALDH1A1USP2LMNAHTT | |
| SCHEMBL19078974 | 0.88 | ALDH1A1 (0.69) | MAPTALDH1A1LMNAHTT | |
| SCHEMBL13223680 | 0.88 | ALDH1A1 (0.69) | MAPTALDH1A1LMNAHTT | |
| SCHEMBL12207107 | 0.86 | CA12 (0.61) | MAPTALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL18498935 | 0.86 | IDO1 (0.56) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL9464524 | 0.85 | CA12 (0.61) | MAPTALDH1A1LMNAGAAKDM4E | |
| SCHEMBL8576412 | 0.85 | ALDH1A1 (0.56) | MAPTALDH1A1USP2LMNAHTT | |
| SCHEMBL3103190 | 0.84 | MEP1B (0.67) | MAPTALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL4541169 | 0.83 | ALDH1A1 (0.73) | MAPTALDH1A1USP2LMNAHTT | |
| SCHEMBL15869133 | 0.83 | ALDH1A1 (0.64) | MAPTALDH1A1USP2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385055-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-08-20 | — | — | US | disclosed |
| US-5783699-A | MAY BE CONJUGATED TO ANTIGENS, HAPTENS, ANTIBODIES IN IMMUNOASSAYS | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| US-5669819-A | IMMUNOASSAY | ABBOTT LABORATORIES (US) | 1997-09-23 | — | — | US | disclosed |
| US-5565570-A | REACTING AMINE WITH SULFONYL HALIDE IN INERT SOLVENT IN PRESENCE OF BASE TO FORM METAL SALT OF SULFONAMIDE, ACYLATING WITH ACTIVATED PHENANTHRIDINE-6-CARBOXYLIC ACID TO FORM CHEMILUMINESCENT SALT | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545739-A | E.G., 5-METHYL-6-(N-2-CARBOXYETHYL-N=(2-CARBOXYETHYL)-PHENANTHRIDIN IUMCARBOXAMIDE CHLORIDE; IMMUNOASSAYS; STABILITY; SENSITIVITY | ABBOTT LABORATORIES (US) | 1996-08-13 | — | — | US | disclosed |
| US-5543524-A | FORMING A SULFONAMIDE FROM AND AMINE AND A SULFONYL HALIDE AND AND ACYLATING WITH A CARBONYL HALIDE OF AN ACTIVATED ACRIDINE SALT | ABBOTT LABORATORIES (US) | 1996-08-06 | — | — | US | disclosed |
| US-5468646-A | Chemiluminescent acridinium salts | ABBOTT LABORATORIES (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0273115-B1 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LAB (US) | 1994-09-07 | — | — | EP | disclosed |
| EP-0273115-A2 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LABORATORIES (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385055-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | MAPT 2765/4885ALDH1A1 1898/4885USP2 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.